Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T17:07:35.999Z.
Calculation as of: 2026-10-06T17:07:35.999Z.
Quote observation: 2026-10-06T17:03:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5a4a1852cf81cc3bdb1e5d7e5b94f2a11abdcd35c6fdd639146ba2a4a55dbff9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jupiter Neurosciences, Inc. (JUNS) | $1.27M | N/A | N/A | N/A | N/A |
| NewcelX Ltd. (NCEL)vs › | $1.32M | N/A | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.34M | N/A | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.38M | N/A | N/A | N/A | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.16M | N/A | 8.30% | 8.30% | 8.30% |
| INVO Fertility, Inc. (IVF)vs › | $1.45M | N/A | N/A | N/A | N/A |
| NEXGEL, Inc. (NXGL)vs › | $1.43M | N/A | N/A | N/A | N/A |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.14M | N/A | N/A | N/A | N/A |
| Curis, Inc. (CRIS)vs › | $1.47M | N/A | 0.69% | 0.69% | 0.69% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.10M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
